1H-MRSI of prostate cancer: The relationship between metabolite ratio and tumor proliferation

European Journal of Radiology

Volumn 73, Issue 2, 2010, Pages 345-351

  Wang, Xi Zhen ^a,b   Wang, Bin ^b   Gao, Zhi Qin ^c   Liu, Jin Gang ^b   Liu, Zuo Qin ^a   Niu, Qing Liang ^d   Sun, Zhen Kui ^b   Yuan, Yu Xiao ^b  

^a SHANDONG UNIVERSITY   (China)

^b Weifang Medicine College   (China)

^c WEIFANG MEDICAL UNIVERSITY   (China)

^d Weifang Municipal Hospital of Traditional Chinese Medicine   (China)

Author keywords

Magnetic resonance imaging; Magnetic resonance spectroscopy; Prostate cancer; Tumor proliferation

Indexed keywords

AVERAGE VALUES; BENIGN PROSTATE HYPERPLASIA; COMMERCIAL SOFTWARE; PHASED ARRAYS; PROLIFERATIVE ACTIVITY; PROSTATE CANCER; PROSTATE CANCERS; SPECTROSCOPIC IMAGING; SUPINE POSITION; TUMOR PROLIFERATION;

ABERRATIONS; CHROMIUM; MAGNETIC RESONANCE; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MAGNETISM; PARTICLE DETECTORS; THREE DIMENSIONAL; TUMORS;

SUPERCONDUCTING MAGNETS;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTON NUCLEAR MAGNETIC RESONANCE; SUPINE POSITION; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; ALGORITHMS; CHOLINE; CITRIC ACID; CREATINE; DIAGNOSIS, COMPUTER-ASSISTED; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 76349110527     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.10.035     Document Type: Article

References (20)

1. Blute M.L., Bergstralh E.J., Iocca A., Scherer B., and Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165 1 (2001) 119-125
2. Engelbrecht M.R., Jager G.J., Laheij R.J., Verbeek A.L., van Lier H.J., and Barentsz J.O. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 12 9 (2002) 2294-2302
3. Nakashima J., Tanimoto A., Imai Y., et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 64 1 (2004) 101-105
4. Casciani E., Polettini E., Bertini L., et al. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiol Med (Torino) 108 5-6 (2004) 530-541
5. Wang L., Hricak H., Kattan M.W., et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 242 1 (2007) 182-188
6. Mueller-Lisse U.G., Swanson M.G., Vigneron D.B., et al. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 46 1 (2001) 49-57
7. Kurki P., Vanderlaan M., Dolbeare F., Gray J., and Tan E.M. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res 166 1 (1986) 209-219
8. Taftachi R., Ayhan A., Ekici S., Ergen A., and Ozen H. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67. BJU Int 95 4 (2005) 650-654
9. Sulik M., and Guzinska-Ustymowicz K. Expression of Ki-67 and PCNA as proliferating markers in prostate cancer. Rocz Akad Med Bialymst 47 (2002) 262-269
10. Sugahara T., Korogi Y., Kochi M., et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imag 9 1 (1999) 53-60
11. Scheidler J., Hricak H., Vigneron D.B., et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213 2 (1999) 473-480
12. Swanson M.G., Vigneron D.B., Tabatabai Z.L., et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues 50 5 (2003) 944-954
13. Shukla-Dave A., Hricak H., Kattan M.W., et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 99 4 (2007) 786-793
14. Sijens P.E., Knopp M.V., Brunetti A., et al. 1H MR spectroscopy in patients with metastatic brain tumors: a multicenter study. Magn Reson Med 33 6 (1995) 818-826
15. Rutter A., Hugenholtz H., Saunders J.K., and Smith I.C. One-dimensional phosphorus-31 chemical shift imaging of human brain tumors. Invest Radiol 30 6 (1995) 359-366
16. Ackerstaff E., Glunde K., and Bhujwalla Z.M. Choline phospholipid metabolism: a target in cancer cells?. J Cell Biochem 90 3 (2003) 525-533
17. Costouros N.G., Coakley F.V., Westphalen A.C., et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. Am J Roentgenol 188 3 (2007) 812-816
18. Garcita-segura J.M., Chapado M.S., Iharburen C., et al. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versue benign pathology. Magnetic Resonance Imaging 17 5 (1999) 755-765
19. Zakian K.L., Sircar K., Hricak H., et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234 3 (2005) 804-814
20. Tanimoto A., Nakashima J., Kohno H., Shinmoto H., and Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imag 25 1 (2007) 146-152